Cargando…
Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism
INTRODUCTION: A patient-reported outcome (PRO) measure specific to chronic hypoparathyroidism is lacking to facilitate the evaluation of treatment. A PRO measure that followed the recommendations of the US Food and Drug Administration (FDA) PRO guidance was created to address key hypoparathyroidism...
Autores principales: | Martin, Susan, Chen, Kristina, Harris, Nimanee, Vera-Llonch, Montserrat, Krasner, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822864/ https://www.ncbi.nlm.nih.gov/pubmed/31183782 http://dx.doi.org/10.1007/s12325-019-00999-2 |
Ejemplares similares
-
Psychometric evaluation of the hypoparathyroidism symptom diary
por: Coles, Theresa, et al.
Publicado: (2019) -
Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism
por: Vokes, Tamara J, et al.
Publicado: (2017) -
Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
por: Winnette, Randall, et al.
Publicado: (2021) -
Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1–84)
por: Chen, Kristina S, et al.
Publicado: (2020) -
Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews
por: Romano, Carla, et al.
Publicado: (2022)